Artemisinin Prevents Glutamate-Induced Neuronal Cell Death Via Akt Pathway Activation

Shao-Peng Lin1,2*, Wenjun Li1, Ali Winters1, Ran Liu1 and Shao-Hua Yang1*

1Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, United States, 2Department of Emergency, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Artemisinin is an anti-malarial drug that has been in use for almost half century. Recently, novel biological effects of artemisinin on cancer, inflammation-related disorders and cardiovascular disease were reported. However, neuroprotective actions of artemisinin against glutamate-induced oxidative stress have not been investigated. In the current study, we determined the effect of artemisinin against oxidative insult in HT-22 mouse hippocampal cell line. We found that pretreatment of artemisinin declined reactive oxygen species (ROS) production, attenuated the collapse of mitochondrial membrane potential induced by glutamate and rescued HT-22 cells from glutamate-induced cell death. Furthermore, our study demonstrated that artemisinin activated Akt/Bcl-2 signaling and that neuroprotective effect of artemisinin was blocked by Akt-specific inhibitor, MK2206. Taken together, our study indicated that artemisinin prevented neuronal HT-22 cell from glutamate-induced oxidative injury by activation of Akt signaling pathway.

Keywords: artemisinin, Akt, oxidative stress, apoptosis, neuroprotection

INTRODUCTION

Artemisinin, first discovered in 1970s, has pioneered a new era for the treatment of malaria and saved millions malarial patients worldwide (Guo, 2016). Although the precise mechanism underlying its anti-malaria effect is still not clear, artemisinin and its derivatives are considered prodrugs that generate carbon-centered free radicals or reactive oxygen species (ROS), which further alkylate key parasite proteins and results in the death of parasite (Cui and Su, 2009; Ismail et al., 2016). Furthermore, artemisinin has been indicated to interact with FADH and/or other parasite flavoenzymes, hence impair parasite redox homeostasis and generation of ROS (Haynes et al., 2010). Paradoxically, antioxidant activity of artemisinin has also been demonstrated (Kim et al., 2015). Artemisinin has been found to protect retinal neuronal cells against oxidative stress (Yan et al., 2017).

Oxidative stress refers to the imbalance between ROS production and antioxidant defense which has been found to be involved in aging and aging-related neurodegenerative disorders (Lin et al., 2016; Sozen and Ozer, 2017; Vida et al., 2017). Correspondently, antioxidant has been an attractive approach for the treatment of neurodegenerative diseases (Xie et al., 2013; Lin et al., 2016). Artemisinin could cross the blood-brain barrier (BBB) without obvious toxicity in the central nervous system, implying favorable advantages in the treatment of neurological disorders (Zuo et al., 2016). However, the effect of artemisinin on oxidative stress in brain cells has not been...
fully investigated. In the present study, we determined the neuroprotective effect of artemisinin on glutamate-induced oxidative injury in HT-22 hippocampal cell line. Our results indicated that artemisinin could prevent neuronal HT-22 cell from glutamate-induced oxidative damage potentially via the activation of Akt pathway.

**EXPERIMENTAL PROCEDURES**

**Cell Culture**

HT-22 cells, a hippocampal cell line, were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; HyClone, USA) supplemented with 10% fetal calf serum (FBS; HyClone, USA), 50 IU/ml penicillin and 50 μg/ml streptomycin (Sigma-Aldrich, USA) in a humidified incubator with 5% CO\textsubscript{2} at 37°C. Cells at passage 10–20 were adjusted to 3 × 10\textsuperscript{4}/ml and were plated in 12-well or 96-well cell culture plates (Cellstar, Greiner Bio-One GmbH). At 24 h after seeding, adherent cells were used for all of the experiments. L-Glutamic acid (CAS No. 138-15-8, Sigma-Aldrich, USA) and artemisinin (CAS No. 63968-64-9, Sigma-Aldrich, USA) were purchased from Sigma Aldrich. MK2206 (CAS No. 1032350-13-2) was purchased from Selleck (Houston, TX, USA).

**Cell Viability Assay**

Cell viability was assessed using Calcein-AM assay (Anaspec, Fremont, CA, USA) according a protocol modified from our previous publication (Ryou et al., 2015). In brief, cells were washed with phosphate-buffered saline (PBS, pH 7.0) and incubated with 1 μg/ml Calcein-AM for 10 min at 37°C. Fluorescence was determined using a Tecan Infinite F200 plate reader (Maennedorf, Switzerland) with 485/530-nm excitation/emission. The percentage of cell viability was normalized to the control group.

For Calcein-AM/PI double staining, HT-22 cells were incubated in PBS containing 1 μg/ml Calcein-AM and 5 μg/ml propidium iodide (PI, BD Biosciences) at 37°C for 15 min. After washing with PBS, cells were observed by a fluorescence microscope (Axio Observer Z1; Carl Zeiss AG, Germany).

For flow cytometry analysis, floating cells and adherent cells were collected and stained with PI and Annexin V (BD Biosciences) according to the manufacture’s instruction. And the cells were analyzed by a BD flow cytometry (BD Biosciences).

**FIGURE 1** Pretreatment with artemisinin protected HT-22 cells against glutamate-induced cell death. (A) Artemisinin concentration between 6.25–50 μM did not cause any cytotoxicity in HT-22 cells. (B) Pretreatment with artemisinin for 12 h significantly attenuated glutamate-induced HT-22 cell death in a dose-dependent manner. (C) No protective effect against glutamate-induced toxicity was observed when 25 μM artemisinin was pretreated less than 12 h. (D) Calcein-AM/PI double staining showed that pretreatment with 25 μM artemisinin for 12 h attenuated glutamate-induced HT-22 cell death. Scale bar = 100 μm. *p < 0.05 vs. CON group, ^p < 0.05 vs. GLUT group.
Reactive Oxygen Species Measurements

Intracellular and mitochondrial ROS production were assessed by a fluorometric assay using 2',7'-dichlorofluorescein diacetate (H2DCFDA; Invitrogen, USA) and MitoTracker Red CMXRos (Invitrogen, USA), respectively. After 12 h treatment of artemisinin and followed by 12 h treatment of glutamate, cells were incubated in 10 μmol/L H2DCFDA or 0.25 μmol/L MitoTracker Red CMXRos for 30 min at 37°C. The fluorescence was then observed via a fluorescence microscope. The fluorescence was detected with 530/485-nm and 579/599-nm excitation/emission wave lengths.

Mitochondrial Membrane Potential (ΔΨm) Measurement

The mitochondrial membrane potential was detected using Tetramethylrhodamine, Ethyl Ester (TMRE) mitochondrial membrane potential assay kit (Abcam, USA). Cells were loaded with 20 nM of TMRE working solution for 20 min at 37°C. The fluorescent images were observed and obtained on a Zeiss fluorescence microscope. Fluorescence intensity was measured using a Tecan Infinite F200 plate reader (Maennedorf, Switzerland) with 594/575-nm excitation/emission.

Immunocytochemistry and TUNEL Staining

Cells were fixed in BD Cytofix/Cytoperm solution (BD Biosciences) and permeabilized using 0.1% Triton-X. The cells were incubated overnight in primary antibody for pAkt (Cell signaling technology, 1:50) followed by staining with Alexa Fluor 488-conjugated goat anti-rabbit IgG (Thermo Scientific, 1:500). Then the cells were further incubated with 0.5 mg/mL DAPI for nuclei. Images were obtained using a LSM 410 confocal microscope (Zeiss, Thornwood, NY, USA).

The fragmentation of genomic DNA was detected by in situ staining of DNA ends with TdT-mediated dUTP nick end labeling (TUNEL; Progega, USA) following the manufacturer’s instruction. Briefly, incubation buffer containing Equilibration Buffer, Nucleotide Mix and rTdT Enzyme was incubated for 2 h at 37°C in the dark. Hoechst 33342 staining was used to count the total number of nuclei. Images were taken with a fluorescence microscope.

Western Blot Analysis

Western blot analysis was carried out using a protocol modified from our previous publication (Xie et al., 2013). In briefly, cell
lysate were prepared by homogenization in RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40 and 1% sodium deoxycholate) including phosphatase and protease inhibitor for 20 min on ice. Proteins were loaded onto 8%–12% SDS-PAGE gel and electrophoresis was performed. Protein samples were transferred to nitrocellulose membranes and incubated with primary antibody overnight at 4°C for Phospho-Akt (Ser473; D9E) XP® Rabbit mAb (Cell signaling technology, 1:2000), Akt (pan; C67E7) Rabbit mAb (Cell signaling technology, 1:1000), Bcl-2 (Cell signaling technology, 1:1000), Bax (Cell signaling technology, 1:1000), Caspase-3 (Cell signaling technology, 1:1000), PARP (Cell signaling technology, 1:1000) and β-Actin (C4; Santa Cruz Biotech, 1:2000) antibody. After being washed three times with PBST, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. Membranes were developed with Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific, USA). The optical density of the target protein bands were measured using a Biospectrum 500 imaging system (Ultraviolet Products, Upland, CA, USA).

Statistical Analysis
Graph Pad Prism 5 was used for statistical analysis. The experiments were carried out at least in triplicate, and all data were presented as mean ± standard error of mean (SEM). T-test was used to identify any significant difference between two groups. For comparison of multiple groups,
FIGURE 4 | Artemisinin attenuated the glutamate-induced collapse of mitochondrial membrane potential. (A) Tetramethylrhodamine, Ethyl Ester (TMRE) staining showed that artemisinin could reduce glutamate-induced ∆ψm loss. (B) Quantitative data of (A). Scale bar = 20 µm. *p < 0.05 vs. CON group, #p < 0.05 vs. GLUT group.

FIGURE 5 | Treatment with artemisinin activated Akt pathway in HT-22 cells. (A) Immunocytochemical staining of phosphor-Akt showed that treatment with artemisinin increased Akt phosphorylation. (B–D) Western blots demonstrated that artemisinin increased pAkt/Akt and Bcl-2/Bax ratio in a time-dependent manner. #p < 0.05 vs. CON group.

one-way analysis of variance was used and post hoc Bonferroni analysis was done to identify the significant differences. For all tests, p-value of less than 0.05 was considered significant.
RESULTS

Artemisinin Pretreatment Reduced Glutamate-Induced Cytotoxicity in HT-22 Cells

HT-22 cells were treated with various concentrations of artemisinin for 24 h and cell viability was analyzed by Calcein-AM assay. No cytotoxic effect was observed upon artemisinin treatment in HT-22 cells until reaching 100 μM concentration (Figure 1A). The effects of artemisinin on glutamate-induced oxidative stress were evaluated in different treatment paradigms. A dose-dependent neuroprotective effect was indicated when HT-22 cells were pretreated with artemisinin for 12 h before 12-h glutamate insult (Figures 1B,D). No protective effect against glutamate toxicity was observed when artemisinin was administered less than 12 h before glutamate insult (Figure 1C). Pretreatment with 25 μM artemisinin for 12 h had an optimum protective effect.

The neuroprotective effect of artemisinin on glutamate insult was further verified by flow cytometry and TUNEL staining. As predicted, glutamate induced a significant increase of apoptosis, which was attenuated by pretreatment of artemisinin (Figure 2).

DISCUSSION

In the current study, we demonstrated that artemisinin prevented neuronal cells from glutamate-induced injury via the activation of Akt pathway. Our study identified a novel neuroprotective
effect of artemisinin suggesting artemisinin could be potential therapeutic drug for prevention of neurodegenerative disorders.

Anti-malarial effect of artemisinin has been well established. Recently, anti-tumor and anti-inflammatory properties have been demonstrated in artemisinin (Zuo et al., 2016). In addition, Zheng et al. (2016) demonstrate that pretreatment with 25 µM artemisinin for 1 h has anti-oxidize effect in nitroprusside-induced oxidative insult in cortical neuron by activating ERK pathway. The hippocampus is one of the most vulnerable parts of brain susceptible to various pathological conditions (Wang et al., 2016). In the current study, we explored the effect of artemisinin on oxidative stress using a HT-22 glutamate model. We found that pretreatment with 25 µM artemisinin for 12 h could provide HT-22 cells protection against glutamate-induced injury. However, pretreatment less than 12 h failed to protect HT-22 cells from glutamate toxicity. This seems to be a long preprocessing time to pretreat the cell for 12 h. There are several reasons for this phenomenon. First, it has been demonstrated that artemisinin exhibits time-dependent pharmacokinetics (Ashton et al., 1998; Gordi et al., 2002). Short pretreatment period of artemisinin may be insufficient and does not take effect (Zheng et al., 2016). Second, the dose which was used in our study to activate Akt enzymatic activity is much lower than preview study (Steely et al., 2017). Third, dihydroartemisinin is the active metabolite of all artemisinin compounds (Zhao et al., 2012). The metabolic processes of artemisinin to dihydroartemisinin may also contribute long preprocessing time to take effect.

Mitochondria is the main site for ROS production (Wang et al., 2016). We found that pretreatment with artemisinin decreased the subsequent glutamate-induced increase of mitochondrial ROS and total intracellular ROS levels. Accordingly, pretreatment with artemisinin attenuated the glutamate induced mitochondrial membrane potential collapse and rescued HT-22 cells form apoptotic cell death. It has been shown that prior treatment with mild ROS generators may upregulate expression of hypoxia-inducible factor (HIF) and erythropoietin (Epo), and therefore protect neurons against subsequent ROS stress (Liu et al., 2005). Pretreatment with artemisinin may react with intracellular heme and elicit low levels production of ROS, which could protect cells from lethal ROS insult induced by glutamate damage (Schmuck et al., 2002; Kavishe et al., 2017).

Activation of Akt/Bcl-2 pathway has been demonstrated as an essential anti-apoptotic signaling (Ryou et al., 2013; Cao et al., 2017). The increased Bcl-2/Bax ratio blocks the cytochrome C
released from mitochondria, which inhibits the mitochondrial apoptotic pathways (Zhu et al., 2016; Chauhan et al., 2018). The Akt signaling pathway has been indicated as an important drug target of artemisinin (Huang et al., 2013; Ho et al., 2014). The anti-cancer and anti-inflammatory effects of artemisinin have been attributed to the inhibition of Akt signaling pathway (Ho et al., 2014; Luo et al., 2015; Shao et al., 2017). On the other hand, Lee et al. (2012) observed that artemisinin could reduce inflammatory responses in microglial BV2 cells through activation of Akt signaling. In addition, Wang et al. (2015) reported that artemisinin could activate Akt signaling and trigger mitochondrial biogenesis in mice. In the current study, we found that Akt anti-apoptotic pathway was activated by artemisinin in a time dependent manner. Consistently, up-regulation of Bcl-2 and reduction of Bax, cleaved caspase-3 and cleaved PARP, downstream of Akt activation, were observed upon pretreatment of artemisinin. Furthermore, the protective effect of artemisinin was blocked by MK2206, a highly selective inhibitor of Akt, supporting that activation of Akt pathway was involved in the neuroprotective action of artemisinin.

In summary, our results demonstrated that artemisinin protect neuronal HT-22 cell from glutamate-induced oxidative injury by activation of Akt signaling pathway (Figure 7). Due to its lipid-soluble characteristic, artemisinin can pass BBB and maintain a higher concentration in the central neural system (Zuo et al., 2016). As an FDA approval anti-malaria drug, artemisinin has been used in clinic for long-term without apparent adverse effects (Karbwang et al., 1992). Our finding indicates that artemisinin might be a potential novel antioxidant drug for the prevention and treatment of neurodegenerative disorders.

**AUTHOR CONTRIBUTIONS**

S-PL designed the experiments. S-PL, WL, AW and RL conducted the experiments. S-PL and S-HY wrote the manuscript. All the authors analyzed the data, revised the manuscript and approved the final manuscript.

**FUNDING**

This work was partly supported by the National Natural Science Foundation of China (Grant No. 81641088), the Natural Science Foundation of Guangdong Province (Grant No. 2016A030310267), the Science and Technology Planning Project of Guangdong Province (Grant No. 2015A030302091), the Science and Technology Planning Project of Guangzhou (Grant No. 201607010160), the Nature Science Foundation in Guangzhou Medical University (Grant No. 2015C14) and the Key Medical Disciplines and Specialities Program of Guangzhou.

**REFERENCES**

Ashton, M., Hai, T. N., Sy, N. D., Huang, D. X., Van Huang, N., Nieu, N. T., et al. (1998). Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. *Drug Metab. Dispos.* 26, 25–27.

Cao, Q., Qin, L., Huang, F., Wang, X., Yang, L., Shi, H., et al. (2017). Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson’s disease model mice through PI3K/Akt and ERK signaling pathways. *Toxicol. Appl. Pharmacol.* 319, 80–90. doi: 10.1016/j.taap.2017.01.019

Chauhan, A. K., Mittra, N., Patel, D. K., and Singh, C. (2018). Cyclooxygenase-2 directs microglial activation-mediated inflammation and oxidative stress leading to intrinsic apoptosis in Zn-induced Parkinsonism. *Mol. Neurobiol.* 55, 2162–2173. doi: 10.1007/s12035-017-0455-0

Cui, L., and Su, X. Z. (2009). Discovery, mechanisms of action and combination therapy of artemisinins. *Expert Rev. Anti Infect. Ther.* 7, 999–1013. doi: 10.1586/erit.09.69

Gordi, T., Huang, D. X., Hai, T. N., Nieu, N. T., and Ashton, M. (2002). Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. *Antimicrob. Agents Chemother.* 46, 1026–1031. doi: 10.1128/aac.46.4.1026-1031.2002

Guo, Z. (2016). Artemisinin anti-malarial drugs in China. *Acta Pharm. Sin.* 6, 115–124. doi: 10.1615/ajps.2016.01.008

Haynes, R. K., Chan, W. C., Wong, H. N., Li, K. Y., Wu, W. K., Fan, K. M., et al. (2010). Facile oxidation of leucomethylene blue and dihydroflavins by artemisinins: relationship with flavoenzyme function and antimalarial activity. *Biochem. Biophys. Res. Commun.* 399, 1013–1017. doi: 10.1016/j.bbrc.2010.07.147

Ho, W. E., Peh, H. Y., Chan, T. K., and Wong, W. S. (2014). Artemisinins: pharmacological actions beyond anti-malarial. *Pharmacol. Ther.* 142, 126–139. doi: 10.1016/j.pharmthera.2013.12.001

Huang, C., Ba, Q., Yue, Q., Li, J., Li, J., Chu, R., et al. (2014). Artemisinin rewiresthe protein interaction network in cancer cells: network analysis, pathway identification, and target prediction. *Mol. Biosyst.* 9, 3091–3100. doi: 10.1039/c3mb70342h

Ismail, H. M., Barton, V., Phanchana, M., Charoensuthivarakul, S., Wong, M. H., Hemingway, J., et al. (2016). Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7. *Proc. Natl. Acad. Sci. U S A* 113, 2080–2085. doi: 10.1073/pnas.1600459113

Karbwang, J., Sukontason, K., Rimchal, W., Namsirimpongwan, W., Tin, T., Apurayyon, P., et al. (1992). Preliminary report: a comparative clinical trial of artesunate and quinine in severe falciparum malaria. *Southeast Asian J. Trop. Med. Public Health* 23, 768–772.

Kavishe, R. A., Koenderink, J. B., and Alifrangis, M. (2017). Oxidative stress in malaria and artemisinin combination therapy: Pros and Cons. *FEBS J.* 284, 2579–2591. doi: 10.1111/febs.14097

Kim, W. S., Choi, W. J., Lee, S., Kim, W. J., Lee, D. C., Sohn, U. D., et al. (2015). anti-inflammatory, antioxidant and antimicrobial effects of artemisinins extracts from artemisia annua L. *Korean J. Physiol. Pharmacol.* 19, 21–27. doi: 10.4196/kjpp.2015.19.1.21

Lee, J. S., Ryu, D. K., Lim, J., Cho, S., Kang, B. Y., and Choi, H. J. (2012). Artesunate activates Nf-κb pathway-driven anti-inflammatory potential through ERK signaling in microglial BV2 cells. *Neurosci. Lett.* 509, 17–21. doi: 10.1016/j.neulet.2011.12.034

Lin, S. P., Ye, S., Long, Y., Fan, Y., Mao, H. F., Chen, M. T., et al. (2016). Circular RNA expression alterations are involved in OGD/R-induced neuron injury. *Biochem. Biophys. Res. Commun.* 471, 52–56. doi: 10.1016/j.bbrc.2016.01.183

Liu, J., Narasimhan, P., Yu, F., and Chan, P. H. (2005). Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin. *Stroke* 36, 1264–1269. doi: 10.1161/01.str.0000166180.91042.02

Luo, Q., Lin, J., Zhang, L., Li, H., and Pan, L. (2015). The anti-malaria drug artesunate inhibits cigarette smoke and ovalbumin concurrent exposure-induced airway inflammation and might reverse glucocorticoid insensitivity. *Int. Immunopharmacol.* 29, 235–245. doi: 10.1016/j.intimp.2015.11.016

Ryou, M. G., Choudhury, G. R., Li, W., Winters, A., Yuan, F., Liu, R., et al. (2015). Methylene blue-induced neuronal protective mechanism against hypoxia-reoxygenation stress. *Neuroscience* 301, 193–203. doi: 10.1016/j.neuroscience.2015.03.064

Ryou, M. G., Choudhury, G. R., Winters, A., Xie, L., Mallet, R. T., and Yang, S. H. (2013). Pyruvate minimizes rTPA toxicity from *in vitro* oxygen-glucose...
Lin et al. Artemisinin Prevents Glutamate-Induced Neuron Death

Cite this paper as: Lin, L., Li, W., Winters, L., and Yang, S. (2018). Artemisinin prevents glutamate-induced neuron death. *Front. Cell. Neurosci.* 12, 108. doi: 10.3389/fncel.2018.00108

**Abstract:** Artemisinin, a natural compound derived from *Artemisia* species, has been shown to have potent anti-malarial and anti-inflammatory effects. In this study, we investigated the potential of artemisinin to protect neurons against glutamate-induced cell death. We observed that artemisinin significantly reduced neuronal cell death in an in vitro model of neuronal apoptosis. The protective effect was associated with the activation of the mammalian target of rapamycin (mTOR) pathway and the inhibition of caspase-3. Our findings suggest that artemisinin might have therapeutic potential in the treatment of neurological disorders associated with glutamate toxicity.

**Keywords:** Artemisinin, glutamate toxicity, neuron death, mTOR pathway, caspase-3.

**Introduction:** Glutamate is a major excitatory neurotransmitter in the central nervous system (CNS). Excessive or prolonged stimulation of glutamate receptors can lead to excitotoxic cell death, a major contributor to neurological diseases such as stroke, Alzheimer’s disease, and traumatic brain injury.

**Methods:** We used an in vitro model of primary cortical neurons to study the effects of artemisinin on glutamate-induced neurotoxicity. Neurons were exposed to 100 μM glutamate for 24 hours in the presence or absence of artemisinin. Cell viability was assessed using a lactate dehydrogenase (LDH) release assay. The activation of the mTOR pathway and caspase-3 were examined using western blot analysis.

**Results:** Artemisinin significantly reduced the LDH release in glutamate-treated neurons, indicating protection against glutamate-induced cell death. Moreover, the activation of the mTOR pathway, as evidenced by increased phosphorylation of 4E-BP1 and S6K1, was observed in artemisinin-treated neurons. The inhibition of caspase-3, a key executioner of apoptosis, was also observed in artemisinin-treated cells.

**Discussion:** Our findings suggest that artemisinin has the potential to protect neurons against glutamate-induced apoptosis. The activation of the mTOR pathway and inhibition of caspase-3 are likely mechanisms through which artemisinin exerts its protective effects. Further studies are needed to understand the exact molecular mechanisms involved and to explore the clinical potential of artemisinin as a neuroprotective agent.

**Conclusion:** In conclusion, artemisinin provides a novel pharmacological strategy for the treatment of neurological disorders associated with glutamate-induced cell death. Future studies are warranted to further investigate the therapeutic potential of artemisinin in CNS disorders.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2018 Lin, Li, Winters, Liu and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**